-
Roscovitine (Seliciclib): Evidence and Research Context
2026-10-07
A source-grounded overview of Roscovitine, also called Seliciclib or CYC202, covering its reported cyclin-dependent kinase activity, conceptual uses in cell-cycle and cancer biology research, evidence from a supplier description, and the broader small-molecule library framework described by Moret et al. It distinguishes reported findings from interpretation and outlines important evidence limitations.
-
Adefovir: Antiviral Mechanism and PK Evidence
2026-10-07
A source-grounded overview of Adefovir and GS-0393, covering its proposed HBV polymerase mechanism, OAT1 transporter research, findings from a 2024 population pharmacokinetic reanalysis, and the limits of translating these data across antiviral and pharmacokinetic applications.
-
PGE2 and Pancreatic Ductal Organoid Research
2026-10-07
Prostaglandin E2 is a biologically active lipid mediator with broad relevance to inflammation research and immune regulation. This overview examines where PGE2 may fit conceptually in pancreatic ductal organoid research, while separating those hypotheses from the direct findings of a 2025 study on small-molecule-enhanced organoid generation. The evidence supports a more efficient pancreatic ductal organoid platform, but the supplied study does not establish that PGE2 was included in its cocktail or that PGE2-specific effects were measured.
-
nor-NOHA: Cancer, Vascular, and AML Context
2026-10-06
nor-NOHA is a reversible arginase inhibitor used as a research probe for arginine metabolism, nitric oxide biology, tumor-cell behavior, and vascular function. This overview separates supplier-reported findings from published AML evidence, compares model systems, and explains why CD36-driven immune escape in AML should not be treated as direct evidence for nor-NOHA activity.
-
Alpha-Ketoglutarate: From Pool to Mechanism
2026-10-05
Alpha-ketoglutarate is more than a tricarboxylic acid cycle intermediate. This evidence-focused analysis explains how α-KGA connects carbon–nitrogen metabolism, enzyme systems, and tumor–immune signaling while clarifying what current research can—and cannot—prove.
-
Nuclear mTORC1 and TerminaTOR: Study Insights
2026-10-05
The reference study introduces TerminaTOR, a genetically encodable inhibitor that separates mTORC1 activity by subcellular location. Its findings indicate that lysosomal and nuclear mTORC1 pools produce distinct outputs, with nuclear mTORC1 influencing transcription of genes containing CCAAT motifs.
-
WY-14643: PPARα Mechanism and Evidence
2026-10-04
WY-14643, also called Pirinixic Acid, is a supplier-described PPARα agonist used in lipid metabolism regulation and metabolic disorder research. A mouse study links PPARα activation with hepatomegaly and liver regeneration through YAP-TEAD signaling, but these findings remain preclinical and do not establish clinical efficacy.
-
DiI (DiIC18(3)) Product Overview
2026-10-03
DiI (DiIC18(3)), SKU B8804, is a supplier-described lipophilic orange fluorescent membrane probe. No matched peer-reviewed paper evidence is available for this overview, so its stated applications and performance characteristics remain product-level claims.
-
Targeted EPO mRNA Nanoparticles for Spinal Cord Repair
2026-10-02
The reference study develops mannose-modified lipid nanoparticles that deliver EPO mRNA to CD206-enriched inflammatory macrophages and microglia after spinal cord injury. In mice, localized EPO expression reduced neuroinflammation and ferroptosis-associated damage while improving axonal preservation and motor recovery, although translation beyond the preclinical model remains unestablished.
-
2'-O-Methyladenosine Workflows for RNA Studies
2026-10-01
Use 2'-O-Methyladenosine as an authentic analytical standard, controlled treatment reagent, and transport-assay probe—not as a substitute for transcript-level RNA mapping. This guide combines matrix-aware UHPLC–MS/MS, cell extraction, and troubleshooting strategies for more reproducible RNA modification nucleoside and purine metabolism studies.
-
2X HyperFusion High-Fidelity Master Mix for CRISPR
2026-10-01
The 2X HyperFusion High-Fidelity Master Mix combines proofreading accuracy, processivity, rapid cycling, and blunt-end product generation for cloning, CRISPR construct validation, and precision genotyping. Its strongest differentiation is workflow reliability when sequence errors could compromise downstream editing or mechanistic interpretation.
-
Dihydroethidium in Bone Redox Assays
2026-09-30
Dihydroethidium enables cell-permeable superoxide analysis in osteoblast and osteoclast models. This article explains how to interpret its signal alongside mitochondrial, NF-κB, and apoptosis endpoints rather than treating fluorescence as a standalone proof of mechanism.
-
WST-8 Glucose Uptake Assay Kit for Metabolic Studies
2026-09-30
The WST-8 Glucose Uptake Assay Kit provides a rapid, non-radioactive way to quantify 2-deoxyglucose handling in cultured cells. Its 450 nm colorimetric readout is especially useful for linking insulin resistance, hepatic steatosis, autophagy disruption, and cancer metabolism to a measurable cellular phenotype.
-
From CRISPR Hits to Chemokine-Aware Brucella Models
2026-09-29
A translational framework for testing whether SDF-1beta (CXCL12) reshapes host-factor dependencies identified in Brucella macrophage infection screens.
-
How In Vitro Drug Response Is Measured in Cancer
2026-09-29
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from actual cancer-cell killing. This framework shows why assay timing and endpoint selection can substantially change how drug response is interpreted and offers a practical basis for designing more informative in vitro studies.